Peter C. Adamson named global development therapeutic area head of oncology and pediatric innovation at Sanofi

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Peter Adamson

Peter C. Adamson was named global development therapeutic area head of oncology and pediatric innovation at Sanofi. Based in Cambridge, MA, Adamson will lead the global development in cancer, and will work with leaders across therapeutic areas to further pediatric drug development efforts.

Adamson joins Sanofi from the Perelman School of Medicine of the University of Pennsylvania, where he was professor of pediatrics and pharmacology, and held the Alan R. Cohen Endowed Chair in Pediatrics at Children’s Hospital of Philadelphia. For almost 10 years prior to joining Sanofi, Adamson chaired the Children’s Oncology Group, an NCI-supported international consortium of more than 220 centers that conduct clinical-translational research, including large-scale clinical trials, in children and adolescents with cancer.

Adamson is board certified in hematology/oncology and clinical pharmacology. He was appointed by President Obama to the National Cancer Advisory Board, where he continues to serve. Adamson also served on the blue-ribbon panel for the Beau Biden National Cancer Moonshot Initiative.

Table of Contents

YOU MAY BE INTERESTED IN

Leadership is changing at The Wistar Institute and the Helen F. Graham Cancer Center & Research Institute in the months to come—but the leaders of the two institutions say that this will have little if any effect on the clinical-research collaboration that they have spent the past 15years building (The Cancer Letter, July 12, 2019). 
March is National Colorectal Cancer Awareness Month. It is a reminder of a heartbreaking trend that oncologists like me are witnessing in our clinics: Last year, for the first time, colorectal cancer became the leading cause of cancer-related death in Americans under the age of 50, according to data published earlier this year in JAMA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login